Redefining hyperkalaemia care with emerging therapies

Hyperkalaemia, a condition of elevated potassium levels in the blood, is one of the most challenging electrolyte disorders in nephrology and cardiology, especially among patients with chronic kidney disease (CKD) and heart failure (HF). Its recurrent nature, and the lack of well-tolerated, long-term treatment options often forces clinicians into a careful trade-off: controlling potassium while maintaining guideline-directed medical therapies (GDMT) that drive survival benefits.

Hyperkalaemia is estimated to affect 6% to 7% of the global population and frequently develops with few or no specific symptoms in the early stages. The challenge lies in recognising these symptoms, as they are mild and easily overlooked. This is especially important for individuals with CKD and HF, who are at a much higher risk of developing this condition. By being aware of the symptoms, patients with CKD and HF can take proactive steps to address the issue before it leads to serious heart problems.

CKD and hyperkalaemia

CKD is the most common driver of hyperkalaemia as declining renal function reduces potassium excretion. Prevalence rises with disease severity, roughly 12%–18% in CKD overall and far higher in advanced stages. Overall, almost 40%–50% of CKD patients may experience hyperkalaemia over the course of their disease. Among patients with HF receiving RAAS (Renin-angiotensin-aldosterone system) inhibitor therapy, the prevalence of hyperkalemia is also substantial, estimated at around 40%. Additional contributors include high-potassium diets, medications that impair potassium elimination, uncontrolled diabetes, Addison’s disease, and severe tissue injury.

The symptoms range from nausea, palpitations (fast heartbeats), muscle pain, and peripheral tingling to more severe complications such as arrhythmia (irregular heartbeat), paralysis, and even cardiac arrest. At present, no medication is approved for routine, long-term management of chronic hyperkalaemia, which poses challenges in maintaining guideline-directed therapies such as RAAS inhibitors and MRAs (Mineralocorticoid Receptor Antagonists) — treatments that are often limited by elevated serum potassium. The clinical stakes are clear: uncontrolled serum potassium destabilises patients and undermines the delivery of therapies proven to improve outcomes.

.

Cardiology and hyperkalaemia

From a cardiology standpoint, the goal is relentless GDMT optimisation to uphold the four pillars of heart failure therapy, RAAS inhibition, beta-blockers, MRAs, and SGLT2 inhibitors. Hyperkalaemia remains a dreadful barrier, often forcing down-titration or discontinuation of therapies that clearly reduce mortality and hospitalisations.

The clinical consequences of suboptimal therapy can be severe: the result is risk escalation and clinical destabilisation. The target should be optimal-dose, long-term GDMT, not compromise. This demands reliable chronic potassium control.

What has changed

Traditional potassium binders have been available for decades, but gastrointestinal adverse effects have limited their use in chronic care. The introduction of newer agents, particularly sodium zirconium cyclosilicate, has altered this landscape. This new medication has demonstrated a favourable safety profile and effective potassium control with a relatively rapid onset of action and can be used on a long-term basis, thereby enabling the continued and optimal use of life-saving therapies that have revolutionised CKD management.

Sodium zirconium cyclosilicate (SZC) is emerging as an enabler for GDMT, helping maintain RAASi and MRAs while preserving safety. By controlling hyperkalaemia consistently, SZC supports continuous therapy rather than reactive interruptions, helping unlock the true benefit of the four-pillar strategy.

Towards better management

Hyperkalaemia is rarely the headline diagnosis, but is often the hidden reason behind suboptimal therapy. Safer, long-term management options now offer clinicians a realistic path to restore treatment continuity and stability. Progress will require more than medicines alone: it calls for better monitoring, earlier detection, and a coordinated commitment to guideline-aligned care. As India faces a rising CKD burden, reliable hyperkalaemia control will increasingly shape outcomes, protecting access to therapies that improve survival and quality of life.

(Dr. Dinesh Khullar is group chairman, nephrology and renal transplant medicine, Max Healhcare Institute Ltd. New Delhi. drdineshkhullar@gmail.com ; Dr Abraham Oomman is senior consultant interventional cardiologist, Apollo Hospitals, Chennai. drabrahamoomman@gmail.com)